Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolution: Pembrolizumab + Chemo in Stage III NSCLC
NCT04153734Phase 2Not yet recruiting
- Sponsor
- Kobe Minimally Invasive Cancer Center
- Start
- Dec 2019
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Kobe Minimally Invasive Cancer Center. Primary endpoint: 2-year Progression-free Survival Rate. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04153734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04153734.